Severe Influenza| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2032

Severe Influenza- Primary Research (KOL's Insight) - Market Intelligence - Epidemiology & Market Forecast-2032

The Severe Influenza market is hugely contributed by the current standard of care (Neuraminidase inhibitor) which is limited to symptom management as there is no approved therapy for Severe Influenza. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. The sales of the emerging therapies for the treatment of Severe Influenza in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2018-2032 study period, adding value estimated at a total market of $ 4.8 billion by 2032.

"Influenza, especially severely ill or severe patients suffer from a major unmet need in terms of efficient treatment. Currently approved vaccines provide 10% to 60% efficacy and approved antivirals often encounter significant viral resistance. Hence, we need an effective treatment to reduce the cases to hospital".

Severe influenza is defined as influenza with a severe symptom or syndrome such as respiratory distress or deceased consciousness or accompanying a severe complication such as encephalopathy or renal failure. Severe influenza presents unique challenges for clinicians. While mild influenza can be treated via ambulatory care, patients who develop complications could get severe influenza which can result in hospitalization and even ICU admission. Infants, the elderly, and sufferers of chronic disease are most at risk of severe influenza, as it can result in complications and exacerbations of underlying conditions. In the UK, children under 5 have the highest influenza admission rate (1.9 per 1000), while over two-thirds (72%) of all influenza-attributable deaths in hospitals occurred in patients over the age of 65 who had co-morbidities.

Severe Influenza - Epidemiology

The total Severe Influenza cases in the G7 countries are anticipated to increase to 1,233,662 cases by 2032 for the study period (2018- 2032). As per estimates, the United States accounted for the highest number of Severe Influenza cases in 2018 which was 71,000 cases, and is expected to increase by 2032 for the study period. Among the EU5, Germany had the highest number of Severe Influenza cases, followed by France, the UK, Italy, and Spain. Japan is reported to have the highest number of cases after the United States.

Current treatments for Severe Influenza are limited and, to date, no FDA-approved drugs have proven effective in Severe Influenza. All the patients suffering from severe influenza (SI) will receive the first line of therapy with the initiation of antiviral treatment with oral or enterically-administered oseltamivir, Peramivir, Laninamivir, Baloxavir, and Zanamivir. The drugs have been used alone or in combination to treat Severe Influenza patients with efficiency.

Severe Influenza - Current Market Size & Forecast Trends

The Severe Influenza therapeutics market is expected to experience high growth throughout our study period (i.e. 2018 to 2032) to USD 4.8 billion, representing compound annual growth (CAGR) of 7.8%.

The United States captured the highest market share in 2022 as compared to the European 5 countries and Japan. We expect that with the launch of the new therapies, the current treatment landscape will expand, catering to the need for the treatment of the Severe Influenza patients group. By 2032, the market share of the United States is expected to increase to USD 3.7 billion whereas the European 5 countries and Japan will have USD XX billion and USD XX million market size in 2032, respectively.

In critically ill patients with influenza, early enteral oseltamivir for at least 5 days is the mainstay of antiviral treatment. Treatment duration should be extended if viral tests remain positive. Resistance to oseltamivir should be considered in the case of prolonged persistence. Intravenous peramivir is the alternative when the enteral route cannot be used.

In 2019, EMA approved intravenous (i.v.) zanamivir for the treatment of complicated and potentially life-threatening influenza caused by either influenza A or B viruses in adults and children from 6 months of age. Intravenous zanamivir is an investigational parenterally administered neuraminidase inhibitor product that has been available in the past through enrollment in a clinical trial or under an emergency investigational new drug (EIND) request to the manufacturer. However, since the 2017-18 season, intravenous zanamivir is no longer available in the United States.

In the 2018-2032 forecast period, we expect an increase in the diagnosis rate of Severe Influenza, and usage of the current standard of care including antiviral agents like Neuraminidase inhibitors (NAIs) will drive the Severe Influenza market. The emerging therapies which are expected to enter the market from 2022-2032 period are Combination Therapy Baloxavir + Oseltamivir (Genentech, Inc.), SAB 176 (SAB Biotherapeutics), Oplunofusp (Ansun Biopharma, Inc.), POLB 001 (Poolbeg Pharma).

Report Highlights

• Severe Influenza - Current Market Trends

• Severe Influenza - Current & Forecasted Cases across the G7 Countries

• Severe Influenza - Market Opportunities and Sales Potential for Agents

• Severe Influenza - Patient-based Market Forecast to 2032

• Severe Influenza - Untapped Business Opportunities

• Severe Influenza - Product Positioning Vis-a-vis Competitors' Products

• Severe Influenza - KOLs Insight